FDA tana share maganin raunukan tiyata a cikin marasa lafiya masu ciwon sukari, ciwon sukari da kiba

Ilya Pharma AB (Kamfanin), wani kamfani na rigakafin rigakafi na asibiti a yau ya sanar da cewa FDA ta share IND don ɗan takararta na jagora ILP100-Topical kuma kamfanin nan da nan yana haɓaka shirye-shirye don babban binciken matakin daidaitawa na 2, wanda aka tsara azaman gwaji mai mahimmanci. ILP100-Topical rigakafi ne na aji na farko wanda aka ƙera don magance raunukan tiyata a cikin marasa lafiya masu ciwon sukari, ciwon sukari da kiba. Waɗannan majiyyatan suna jinkirin jinkirin waraka daga makonni zuwa watanni bayan tiyata da haɓakar haɗarin haɗari mai tsanani.

Robert D. Galiano, MD, FACS Mataimakin Farfesa; Daraktan Bincike; Sashen Aikin tiyatar Filastik da ke Arewa maso yammacin Jami'ar Feinberg School of Medicine, za ta zama Mai Binciken Gudanarwa na Kasa da Shugaban Nazarin Nazarin wanda zai hada da marasa lafiya 260. Bayan aikin da ke gudana ta Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararru na FDA (WEF-CEP) da kuma abubuwan da ke faruwa a wasu wurare irin su ciwon daji da cututtukan cututtuka na rheumatoid, zaɓi na farko na ƙarshe shine ƙaddamarwa mai rikitarwa na warkarwa kyauta. Binciken yana da tsari mai daidaitawa kuma ya ƙunshi sassa biyu - na farko shine ɓangaren gano kashi kuma na biyu ɓangaren tabbatarwa. Godiya ga tsarin kulawa na ciki, inda kowane mai haƙuri yana da ikon kansa tare da raunin da aka bi da shi tare da placebo da kuma raunin da aka bi da shi tare da ILP100-Topical, binciken ya ragu sosai, yawan adadin marasa lafiya ya ragu da kuma nuna bambanci tsakanin kungiyoyin jiyya. rage girman

Dokta Galiano ya yi sharhi: “Ba dole ba ne mutum ya kamu da ciwon sukari don ya same shi da nakasu wajen warkar da raunuka, kuma ba wai kawai ba a yaba wa wannan ba, amma kuma ba mu da wasu magungunan da ke yin la’akari da wannan nakasu wajen warkarwa. Tasirin kiba annoba ce ta shiru kuma tana shafar kowane aikin tiyata. Maganin warkewa wanda ke inganta raunin rauni na tiyata zai haifar da ingantacciyar sakamako a cikin duk fannonin tiyata da hanyoyin, ba kawai a rage nono ba. Don haka na yi farin cikin jagorantar wannan gwaji bayan ganin kyakkyawan sakamako da Ilya ya riga ya samu a cikin karatun su na Mataki na I."

Shugaban Ilya Pharma kuma Co-kafa Evelina Vågesjö ta kara da cewa: “Cikin yarda ya zo da sauri fiye da yadda ake tsammani, yanzu muna da niyyar kula da mara lafiya na farko a Q3 a wannan shekara. Wannan kuma wani muhimmin lokaci ne ga Ilya Pharma bayan ƙoƙarce-ƙoƙarce ta babbar ƙungiyarmu. Yin aiki tare tare da Dr Galiano da ƙungiyar ƙwararru da KOLs mun yi imanin mun ƙirƙiri ƙirar gwaji mafi kyau wanda zai nuna fa'idodin canji na gaske na ILP100-Topical ga marasa lafiya, farawa da wannan yawan masu haɗarin. Bugu da kari, wannan ci gaban ya tabbatar da tsarin fasahar mu na ILP da sauran masu neman magani a cikin ci gaban da muka lura suna samun karuwar sha'awa. "